indazoles has been researched along with Female Genital Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, H; Enomoto, T; Ito, YM; Matsumura, N; Oda, K; Shimada, M; Watari, H; Yoshihara, K | 1 |
| Gunderson, CC; Matulonis, U; Moore, KN | 1 |
| Harstead, KE; Stewart, CF; Throm, SL; Tillmanns, TD; Turner, DC | 1 |
| Curtis, LB; du Bois, A; Harter, P; Mitrica, I; Ray-Coquard, I; Vergote, I; Wimberger, P | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
3 review(s) available for indazoles and Female Genital Neoplasms
| Article | Year |
|---|---|
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
Topics: Clinical Trials, Phase II as Topic; Female; Genital Neoplasms, Female; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
1 trial(s) available for indazoles and Female Genital Neoplasms
| Article | Year |
|---|---|
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Early Termination of Clinical Trials; Feasibility Studies; Female; Genital Neoplasms, Female; Humans; Indazoles; Middle Aged; Paclitaxel; Pyrimidines; Sulfonamides | 2012 |
1 other study(ies) available for indazoles and Female Genital Neoplasms
| Article | Year |
|---|---|
Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Female; Genital Neoplasms, Female; Humans; Indazoles; Middle Aged; Pyrimidines; Sulfonamides; Topotecan | 2013 |